

Advaxis, Inc.  
Form 8-K  
June 11, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 10, 2014**

**ADVAXIS, INC.**

**(Exact name of registrant as specified in its charter)**

<b>Delaware</b>	<b>00028489</b>	<b>02-0563870</b>
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

**305 College Road East**

**08540**

**Princeton, New Jersey**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(609) 452-9813**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On June 10, 2014, Advaxis, Inc. (the “Company”) issued a press release to announce that the Company’s request for an End-of-Phase 2 meeting with the U.S. Food and Drug Administration has been granted. Additionally, in the press release, the Company also announced its upcoming goals and provided an overview of the Company’s clinical programs.

A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

The following exhibit is filed herewith:

(d) Exhibits.

**Exhibit No. Description**

99.1 Advaxis, Inc. press release dated June 10, 2014.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ADVAXIS, INC.**

By: */s/ Daniel J. O'Connor*

Name: Daniel J. O'Connor

Title: Chief Executive Officer

Date: June 11, 2014

**EXHIBIT INDEX**

**Exhibit No. Description**

99.1 Advaxis, Inc. press release dated June 10, 2014.

